Discover one of our 28 local entrepreneurial communities »
Be the first to know as we launch in new countries and markets around the globe.
Interested in bringing MIT Technology Review to your local market?
Unsupported browser: Your browser does not meet modern web standards. See how it scores »
Several gene therapies are or will soon be in late-stage human trials. One of them could be the first to get FDA approval for sale in the U.S.
Amgen and Genzyme are pursuing disruptive ways of making biological drugs.
By mimicking genetic variation in people with naturally low levels of cholesterol, drug developers are hoping to create a new drug.